Manufacturer
51 recalls in our database name Noven Pharmaceuticals, Inc. as the manufacturing or recalling firm.
Of the 51 recalls from Noven Pharmaceuticals, Inc. we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 4 (8%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Noven Pharmaceuticals Inc is recalling 685 boxes of XELSTRYM (dextroamphetamine) transdermal patches nationwide due to a defect in the adhesive delivery system. The product does not meet manufacturing specifications.
Noven Pharmaceuticals is recalling specific lots of Daytrana (methylphenidate) transdermal patches due to a defective delivery system that is out of specification for shear. Affected lots are Lot 91956 (6/2023) and Lot 92475 (7/2023), distributed nationwide.
Noven Pharmaceuticals recalls Daytrana (methylphenidate) 30 mg transdermal patches nationwide due to defective delivery system components that fail shear specifications. Patients should contact their healthcare provider regarding medication alternatives.
Noven Pharmaceuticals is recalling Daytrana methylphenidate transdermal patches for a defective delivery system that fails to meet shear specifications. The recall affects specific lots distributed nationwide.
Noven Pharmaceuticals is recalling specific lots of Daytrana methylphenidate transdermal patches distributed nationwide because the delivery system is out of specification for shear. The affected lots require patient and healthcare provider attention.
Noven Pharmaceuticals recalls 3,977 boxes of Daytrana methylphenidate transdermal patches nationwide due to defective adhesive properties in lot 91316. Affected patches may fail to adhere properly or deliver medication inconsistently.
Daytrana (methylphenidate) patches are being recalled due to ripping patches and poor adhesive transfer affecting drug delivery. This Class II recall involves 8,559 cartons distributed nationwide.
Noven Pharmaceuticals is recalling Daytrana methylphenidate transdermal patches from Lot 90764 (expiration 08/2022) distributed nationwide due to defects in the delivery system. The recall was initiated after customer complaints exceeded FDA action limits.
Noven Pharmaceuticals is recalling Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.14 mg per day because certain lots failed stability specifications and tested out of specification for shear.
Noven Pharmaceuticals is recalling certain lots of Combipatch (estradiol/norethindrone acetate transdermal system) distributed nationwide because the patches failed stability testing and fell out of specification for shear properties.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because customer complaints regarding ripped patches and adhesive transfer exceeded action limits.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because customer complaints regarding ripped patches and adhesive issues exceeded action limits.
Noven Pharmaceuticals is recalling Estradiol Transdermal Systems because the adhesive may not stick well to the skin.
Noven Pharmaceuticals is recalling Minivelle estradiol transdermal patches because the adhesive may not stick well to the skin.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because the delivery system is out of specification for mechanical peel.
Noven Pharmaceuticals is recalling 786,900 Daytrana (methylphenidate) patches because the delivery system failed mechanical peel specifications.
Noven Pharmaceuticals is recalling 473,280 Daytrana (methylphenidate) patches because the delivery system failed mechanical peel specifications.
Noven Pharmaceuticals is recalling 551,670 Daytrana methylphenidate patches nationwide because the delivery system failed mechanical peel specifications.
Noven Pharmaceuticals is recalling Minivelle (estradiol) transdermal patches because the adhesive delivery system failed to meet specification standards for shear.
Noven Pharmaceuticals is recalling Minivelle (estradiol) transdermal patches because the adhesive delivery system failed to meet specification standards for shear.
Noven Pharmaceuticals is recalling Minivelle (estradiol) transdermal patches because the adhesive delivery system failed to meet specification standards for shear.
Noven Pharmaceuticals is recalling Minivelle (estradiol) transdermal patches because the adhesive delivery system failed to meet specification standards for shear.
Noven Pharmaceuticals is recalling Minivelle (estradiol) transdermal patches because the adhesive may not stick well to the skin.
Noven Pharmaceuticals is recalling Minivelle (estradiol) transdermal systems because the adhesive may not meet specifications, causing patches to stick poorly to the skin.
Noven Pharmaceuticals is recalling Daytrana (methylphenidate) transdermal patches because the adhesive transfer is out of specification.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
NOVEN PHARMACEUTICALS, INC.
Source: Wikidata (Q140588347), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.